Clinical trial NCT05572515: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Official title: A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Relapsed or Refractory Multiple Myeloma
Lead sponsor: Janssen Research & Development, LLC
Sponsor class: INDUSTRY
First posted: 2022-10-07
Enrollment: 650
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.


Eligibility criteria: Inclusion Criteria:

* Documented diagnosis of multiple myeloma as defined by the criteria below: (a)Multiple myeloma diagnosis according to International Myeloma Working Group (IMWG) diagnostic criteria (b) Measurable disease at screening as defined by any of the following: (1) Serum M-protein level greater than or equal to (\>=)0.5 grams per deciliter (g/dL) (central laboratory); or (2) Urine M-protein level \>=200 milligrams (mg)/24 hours (central laboratory); or (3) Serum immunoglobulin free light chain \>=10 milligrams per deciliter (mg/dL) (central laboratory) and abnormal serum immunoglobulin kappa lambda free light chain ratio
* Received 1 to 3 prior lines of antimyeloma therapy including a minimum of 2 consecutive cycles of an anti- cluster of differentiation 38 (CD38) monoclonal antibody at the approved dosing regimen in any prior line and 2 consecutive cycles of lenalidomide in any prior line
* Documented evidence of progressive disease or failure to achieve a response to last line of therapy based on investigator's determination of response by International myeloma working group (IMWG) criteria
* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
* A female participant must agree not to be pregnant, breast-feeding, or plan to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
* Must be willing and able to adhere to the lifestyle restrictions specified in this protocol

Exclusion Criteria:

* Received any prior B cell maturation antigen (BCMA)-directed therapy
* A participant is not eligible to receive PVd as control therapy if any of the following are present: (1) Received prior pomalidomide therapy, (2) Does not meet criteria for bortezomib retreatment (3) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to pomalidomide or bortezomib, (4) Grade 1 peripheral neuropathy with pain or Grade greater than or equal to (\>=) 2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, (5) Received a strong cytochrome P (CYP) 3A4 inducer within 5 half-lives prior to randomization; A participant is not eligible to receive Kd as control therapy if any of the following are present:(1) Received prior carfilzomib therapy, (2) Uncontrolled hypertension, defined as an average systolic blood pressure greater than (\>)159 millimeters of mercury (mmHg) or diastolic blood pressure \>99 mmHg despite optimal treatment (3) Grade 2 peripheral neuropathy with pain or Grade \>=3 peripheral neuropathy as defined by NCI-CTCAE Version 5.0, (4) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to carfilzomib (intolerance defined as prior therapy discontinued due to any adverse event \[AE\] related to carfilzomib)
* Received a maximum cumulative dose of corticosteroids of \>=140 mg of prednisone or equivalent within 14 days prior to randomization
* Received a live, attenuated vaccine within 4 weeks before randomization
* Central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma
* Plasma cell leukemia at the time of screening, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein (POEMS) syndrome and skin changes, or primary amyloid light chain amyloidosis

Primary outcomes:
measure: Part 1: Progression-free Survival (PFS)
timeFrame: Up to 9 years
measure: Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by Severity
timeFrame: Up to 9 years
Secondary outcomes:
measure: Part 1 and 2: Overall Response (Partial Response [PR] or Better)
timeFrame: Up to 9 years
measure: Part 1 and 2: Very Good Partial Response (VGPR) or Better Response
timeFrame: Up to 9 years
measure: Part 1 and 2: Complete Response (CR) or Better Response
timeFrame: Up to 9 years
measure: Part 1: Duration of Response (DOR)
timeFrame: Up to 9 years
measure: Part 1: Time to Next Treatment (TTNT)
timeFrame: Up to 9 years
measure: Part 1: Progression-free Survival on Next-line Therapy (PFS2)
timeFrame: Up to 9 years
measure: Part 1: Overall Survival (OS)
timeFrame: Up to 9 years
measure: Part 1 and 2: Number of Participants with Adverse Events (AEs) by Severity
timeFrame: Up to 9 years
measure: Part 1 and 2: Number of Participants with Serious Adverse Events (SAEs) by Severity
timeFrame: Up to 9 years
measure: Part 1 and 2: Number of Participants with Abnormal Laboratory Results
timeFrame: Up to 9 years
measure: Part 1 and 2: Serum Concentrations of Teclistamab
timeFrame: Up to 9 years
measure: Part 1 and 2: Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab
timeFrame: Up to 9 years
measure: Part 1: Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)
timeFrame: Baseline up to 9 years
measure: Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score
timeFrame: Baseline up to 9 years
measure: Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
timeFrame: Baseline up to 9 years
measure: Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
timeFrame: Baseline up to 9 years
measure: Part 1: Time to Worsening in Symptoms, Functioning, and Overall HRQoL
timeFrame: Up to 9 years
measure: Part 1: PFS in Participants in High-risk Molecular Features
timeFrame: Up to 9 years
measure: Part 1: Depth of Response in Participants in High-risk Molecular Features
timeFrame: Up to 9 years
Other outcomes:
Locations:
city: Anchorage
country: United States
facility: Alaska Oncology and Hematology LLC
state: Alaska
city: Gilbert
country: United States
facility: Banner MD Anderson Cancer Center
state: Arizona
city: Berkeley
country: United States
facility: Alta Bates Comprehensive Cancer Center
state: California
city: Long Beach
country: United States
facility: MemorialCare Long Beach Medical Center
state: California
city: Orange
country: United States
facility: University of California Irvine
state: California
city: Whittier
country: United States
facility: PIH Health Hospital
state: California
city: Aurora
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Farmington
country: United States
facility: University of Connecticut
state: Connecticut
city: Miami
country: United States
facility: University of Miami Sylvester Cancer Center
state: Florida
city: Orlando
country: United States
facility: Orlando Health Cancer Institute
state: Florida
city: Weston
country: United States
facility: Cleveland Clinic Florida
state: Florida
city: Des Moines
country: United States
facility: Mission Cancer Blood
state: Iowa
city: Metairie
country: United States
facility: East Jefferson General Hospital Bone Marrow Transport Clinic
state: Louisiana
city: Bethesda
country: United States
facility: Walter Reed National Military Medical Center
state: Maryland
city: Silver Spring
country: United States
facility: Maryland Oncology Hematology P A
state: Maryland
city: Boston
country: United States
facility: Boston University Medical Center
state: Massachusetts
city: Chesterfield
country: United States
facility: Saint Lukes Hospital Saint Lukes Cancer Specialists
state: Missouri
city: Camden
country: United States
facility: Cooper Health System MD Anderson Cancer Center at Cooper
state: New Jersey
city: New York
country: United States
facility: Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
state: New York
city: Durham
country: United States
facility: Durham VAMC
state: North Carolina
city: Lancaster
country: United States
facility: Penn Medicine Lancaster General Health
state: Pennsylvania
city: Fort Sam Houston
country: United States
facility: Brooke Army Medical Center
state: Texas
city: Houston
country: United States
facility: Baylor College of Medicine
state: Texas
city: Houston
country: United States
facility: Michael E DeBakey VA Medical Center
state: Texas
city: Houston
country: United States
facility: Harris Health Smith Clinic
state: Texas
city: Salt Lake City
country: United States
facility: Utah Cancer Specialists
state: Utah
city: Fort Belvoir
country: United States
facility: Alexander T. Augusta Military Medical Center
state: Virginia
city: Norfolk
country: United States
facility: Virginia Oncology Associates
state: Virginia
city: Tacoma
country: United States
facility: NorthWest Medical Specialties, PLLC
state: Washington
city: Blacktown
country: Australia
facility: Blacktown Hospital
city: Fitzroy
country: Australia
facility: St Vincents Hospital Melbourne
city: Melbourne
country: Australia
facility: Box Hill Hospital
city: Murdoch
country: Australia
facility: Fiona Stanley Hospital
city: Nedlands
country: Australia
facility: Sir Charles Gairdner Hospital
city: Salzburg
country: Austria
facility: LKH - Universitätsklinikum der PMU Salzburg
city: Vienna
country: Austria
facility: Medical University Vienna MUV
city: Brasschaat
country: Belgium
facility: Algemeen Ziekenhuis Klina
city: Haine-St-Paul
country: Belgium
facility: Jolimont
city: Kortrijk
country: Belgium
facility: Az Groeninge
city: Leuven
country: Belgium
facility: Universitair Ziekenhuis Gasthuisberg
city: Liege
country: Belgium
facility: CHR de la Citadelle
city: Brasilia
country: Brazil
facility: Hospitais Integradaos da Gavea S/A - DF Star
city: Caxias do Sul
country: Brazil
facility: Fundacao Universidade de Caxias do Sul
city: Curitiba
country: Brazil
facility: Liga Paranaense de Combate ao Cancer
city: Joinville
country: Brazil
facility: Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
city: Natal
country: Brazil
facility: Liga Norte Riograndense Contra O Cancer
city: Niteroi
country: Brazil
facility: Complexo Hospitalar de Niteroi
city: Rio de Janeiro
country: Brazil
facility: Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
city: Salvador
country: Brazil
facility: Hospital Sao Rafael
city: Sao Jose do Rio Preto
country: Brazil
facility: Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
city: Sao Paulo
country: Brazil
facility: Sociedade Beneficente de Senhoras Hospital Sirio Libanes
city: Sao Paulo
country: Brazil
facility: Instituto D Or de Pesquisa e Ensino IDOR
city: Sao Paulo
country: Brazil
facility: Fundacao Antonio Prudente A C Camargo Cancer Center
city: Sao Paulo
country: Brazil
facility: Clinica Medica Sao Germano LTDA
city: São Paulo
country: Brazil
facility: Real e Benemérita Associação Portuguesa de Beneficência
city: São Paulo
country: Brazil
facility: Hospital Alemao Oswaldo Cruz
city: São Paulo
country: Brazil
facility: Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
city: Calgary
country: Canada
facility: Arthur J E Child Comprehensive Cancer Centre
state: Alberta
city: Saint John
country: Canada
facility: Saint John Regional Hospital
state: New Brunswick
city: Brampton
country: Canada
facility: Brampton Civic Hospital
state: Ontario
city: Oshawa
country: Canada
facility: Lakeridge Health Oshawa
state: Ontario
city: Montreal
country: Canada
facility: CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
state: Quebec
city: Beijing
country: China
facility: Beijing Chaoyang Hospital
city: Beijing
country: China
facility: BeiJing JiShuiTan Hospital
city: Changchun
country: China
facility: The First Bethune Hospital of Jilin University
city: Changsha
country: China
facility: The Third Xiangya Hospital, Central South University
city: Chengdu
country: China
facility: Sichuan Provincial Peoples Hospital
city: Chongqing
country: China
facility: Chongqing University Cancer Hospital
city: Fu Zhou
country: China
facility: Fujian Meidical University Union Hospital
city: Guangzhou
country: China
facility: Sun Yat -Sen University Cancer Center
city: Hangzhou
country: China
facility: First affiliated Hospital of Zhejiang University
city: Harbin
country: China
facility: Harbin medical university cancer hospital
city: Nanchang
country: China
facility: The First Affiliated Hospital of NanChang University
city: Nanjing
country: China
facility: Nanjing Drum Tower Hospital
city: Nanning
country: China
facility: First Affiliated Hospital of Guangxi Medical University
city: Shanghai
country: China
facility: Shanghai Fourth People s Hospital
city: Shenyang
country: China
facility: Shengjing Hospital Of China Medical University
city: Shenzhen
country: China
facility: Shenzhen 2nd People's Hospital
city: Tian Jin
country: China
facility: Institute of Hematology and Blood Diseases Hospital
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute and Hospital
city: Wenzhou
country: China
facility: The First Affiliated Hospital of Wenzhou Medical University
city: Wuhan
country: China
facility: Wuhan Union Hospital
city: Wuxi
country: China
facility: Wuxi People s Hospital
city: Xi'an
country: China
facility: The Second Affiliated Hospital of Xi'an Jiaotong University
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
city: Brno
country: Czechia
facility: Fakultni nemocnice Brno
city: Olomouc
country: Czechia
facility: Fakultni nemocnice Olomouc
city: Ostrava - Poruba
country: Czechia
facility: Fakultni Nemocnice Ostrava
city: Praha 2
country: Czechia
facility: Vseobecna fakultni nemocnice v Praze
city: Aalborg
country: Denmark
facility: Aalborg University Hospital
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
city: Copenhagen
country: Denmark
facility: Rigshospitalet
city: Herning
country: Denmark
facility: Regionshospitalet Godstrup
city: Odense C
country: Denmark
facility: Odense Universitetshospital
city: Vejle
country: Denmark
facility: Vejle Sygehus
city: AMIENS cedex 1
country: France
facility: CHU Amiens - Hopital Sud
city: Caen cedex 9
country: France
facility: Hôpital Côte de Nacre
city: Grenoble
country: France
facility: CHU Grenoble
city: Le Mans
country: France
facility: Centre Hospitalier du Mans
city: Lille
country: France
facility: Hopital Saint Vincent de Paul
city: Montpellier
country: France
facility: CHU de Montpellier Hopital Saint Eloi
city: Nantes Cedex 1
country: France
facility: CHU Nantes
city: Paris
country: France
facility: Hopital Saint-Antoine
city: Paris
country: France
facility: Hopital de la Pitie Salpetriere
city: Paris
country: France
facility: Hopital Necker Enfants Malades
city: Toulouse
country: France
facility: Institut Universitaire du Cancer Toulouse Oncopole
city: Vandœuvre-lès-Nancy
country: France
facility: CHU de Nancy - Hopital de Brabois
city: Cottbus
country: Germany
facility: Medizinische Universitat Lausitz Carl Thiem
city: Dresden
country: Germany
facility: Universitatsklinikum Carl Gustav Carus Dresden
city: Greifswald
country: Germany
facility: Universitätsmedizin Greifswald
city: Hamburg
country: Germany
facility: Asklepios Klinik Altona
city: Heidelberg
country: Germany
facility: Universitaetsklinikum Heidelberg
city: Marburg
country: Germany
facility: Universitaetsklinikum Giessen und Marburg GmbH
city: Tübingen
country: Germany
facility: Universitatsklinikum Tubingen
city: Ulm
country: Germany
facility: Universitatsklinikum Ulm
city: Zwickau
country: Germany
facility: Heinrich-Braun-Klinikum gGmbH
city: Athens Attica
country: Greece
facility: Alexandra General Hospital of Athens
city: Patra
country: Greece
facility: Agios Andreas General Hospital of Patra
city: Thessaloniki
country: Greece
facility: G Papanikolaou Hospital of Thessaloniki
city: Gurgaon
country: India
facility: Fortis Memorial Research Institute
city: Jaipur
country: India
facility: Bhagwan Mahaveer Cancer Hospital & Research Centre
city: Pune
country: India
facility: Deenanath Mangeshkar Hospital and Research Centre
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
city: Haifa
country: Israel
facility: Bnai Zion Medical Center
city: Haifa
country: Israel
facility: Carmel Medical Center
city: Petah Tikva
country: Israel
facility: Rabin Medical Center
city: Ramat Gan
country: Israel
facility: Sheba Medical Center
city: Tel-Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center
city: Bologna
country: Italy
facility: A O U Sant Orsola Malpighi
city: Milano
country: Italy
facility: Fondazione IRCCS Istituto Nazionale dei Tumori
city: Palermo
country: Italy
facility: Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
city: Pisa
country: Italy
facility: Ospedale Santa Chiara AO Universitaria Pisana
city: Reggio Emilia
country: Italy
facility: Arcispedale Santa Maria Nuova - IRCCS
city: Roma
country: Italy
facility: Campus Bio Medico di Roma
city: Siena
country: Italy
facility: A O Universitaria Senese Ospedale Santa Maria alle Scotte
city: Turin
country: Italy
facility: A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
city: Udine
country: Italy
facility: ASUI Santa Maria della Misericordia di Udine
city: Varese
country: Italy
facility: Ospedale di Circolo e Fondazione Macchi
city: Bunkyo ku
country: Japan
facility: Institute of Science Tokyo Hospital
city: Chiba
country: Japan
facility: Chiba Cancer Center
city: Gifu
country: Japan
facility: Ogaki Municipal Hospital
city: Gunma
country: Japan
facility: National Hospital Organization Shibukawa Medical Center
city: Hirakata
country: Japan
facility: Kansai Medical University Hospital
city: Hitachi
country: Japan
facility: Hitachi General Hospital
city: Iruma-gun
country: Japan
facility: Saitama Medical University Hospital
city: Kamogawa City
country: Japan
facility: Kameda Medical Center
city: Kashiwa
country: Japan
facility: National Cancer Center Hospital East
city: Kurashiki
country: Japan
facility: Kurashiki Central Hospital
city: Matsuyama
country: Japan
facility: Matsuyama Red Cross Hospital
city: Nagakute
country: Japan
facility: Aichi Medical University Hospital
city: Nagasaki-Shi
country: Japan
facility: JRC Nagasaki Genbaku Hospital
city: Niigata
country: Japan
facility: Niigata University Medical And Dental Hospital
city: Okayama
country: Japan
facility: National Hospital Organization Okayama Medical Center
city: Osaka
country: Japan
facility: Osaka Metropolitan University Hospital
city: Sapporo
country: Japan
facility: Hokkaido University Hospital
city: Tokyo
country: Japan
facility: Juntendo University Hospital
city: Tokyo
country: Japan
facility: The Cancer Institute Hospital of JFCR
city: Yamagata
country: Japan
facility: Yamagata University Hospital
city: Yamanashi
country: Japan
facility: Yamanashi Prefectural Central Hospital
city: Georgetown
country: Malaysia
facility: Hospital Pulau Pinang
city: Kota Kinabalu
country: Malaysia
facility: Hospital Queen Elizabeth
city: Kuala Lumpur
country: Malaysia
facility: University Malaya Medical Centre
city: Subang Jaya
country: Malaysia
facility: Subang Jaya Medical Centre
city: Amersfoort
country: Netherlands
facility: Meander Medisch Centrum
city: Amsterdam
country: Netherlands
facility: VUMC Amsterdam
city: Groningen
country: Netherlands
facility: Universitair Medisch Centrum Groningen
city: Utrecht
country: Netherlands
facility: UMC Utrecht
city: Gdansk
country: Poland
facility: Uniwersyteckie Centrum Kliniczne
city: Katowice
country: Poland
facility: Pratia Onkologia Katowice
city: Kielce
country: Poland
facility: Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
city: Lublin
country: Poland
facility: Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie
city: Almada
country: Portugal
facility: Uls Almada Seixal - Hosp. Garcia de Orta
city: Braga
country: Portugal
facility: Uls Braga - Hosp. Braga
city: Lisbon
country: Portugal
facility: Champalimaud Foundation Champalimaud Centre
city: Porto
country: Portugal
facility: Instituto Portugues de Oncologia
city: Vila Nova de Gaia
country: Portugal
facility: Uls Gaia Espinho
city: Badalona
country: Spain
facility: Hosp. Univ. Germans Trias I Pujol
city: Hospitalet de Llobregat
country: Spain
facility: Institut Catala d Oncologia L Hospitalet
city: Jerez de la Frontera
country: Spain
facility: Hosp. de Jerez de La Frontera
city: Leon
country: Spain
facility: Hosp. de Leon
city: Madrid
country: Spain
facility: Hosp. Univ. Infanta Leonor
city: Madrid
country: Spain
facility: Hosp. Univ. Ramon Y Cajal
city: Madrid
country: Spain
facility: Hosp. Univ. 12 de Octubre
city: Murcia
country: Spain
facility: Hosp. Gral. Univ. J.M. Morales Meseguer
city: Oviedo
country: Spain
facility: Hospital Universitario Central de Asturias
city: Palma de Mallorca
country: Spain
facility: Hosp. Son Llatzer
city: Pontevedra
country: Spain
facility: Hosp. Montecelo
city: Pozuelo de Alarcon
country: Spain
facility: Hosp. Quiron Madrid Pozuelo
city: València
country: Spain
facility: Hospital Universitari i Politecnic La Fe
city: Falun
country: Sweden
facility: Falu Lasarett Medicinkliniken Falun
city: Helsingborg
country: Sweden
facility: Helsingborgs lasarett
city: Uppsala
country: Sweden
facility: Akademiska Sjukhuset
city: Ankara
country: Turkey
facility: Ankara Gulhane Training and Research Hospital
city: Ankara
country: Turkey
facility: Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
city: Ankara
country: Turkey
facility: Ankara University Medical Faculty
city: Ankara
country: Turkey
facility: Liv Hospital Ankara
city: Antalya
country: Turkey
facility: Antalya Training And Research Hospital
city: Atakum
country: Turkey
facility: Ondokuz Mayis University
city: Denizli
country: Turkey
facility: Pamukkale University Medical Faculty
city: Istanbul
country: Turkey
facility: Medipol University Hospital
city: Aberdeen
country: United Kingdom
facility: Aberdeen Royal Infirmary
city: Birmingham
country: United Kingdom
facility: University Hospitals Birmingham NHS Foundation Trust
city: Colchester
country: United Kingdom
facility: Colchester Hospital University NHS
city: Liverpool
country: United Kingdom
facility: The Clatterbridge Cancer Centre
city: London
country: United Kingdom
facility: Chelsea And Westminster Hospital
city: London
country: United Kingdom
facility: St George's Hospital
city: Middlesborough
country: United Kingdom
facility: James Cook University Hospital
city: Norwich
country: United Kingdom
facility: Norfolk and Norwich University Hospital
city: Staffordshire
country: United Kingdom
facility: Royal Stoke University Hospital
Study officials:
affiliation: Janssen Research & Development, LLC
name: Janssen Research & Development, LLC Clinical Trial
role: STUDY_DIRECTOR
References: